Clinical trials: Ulcer
Crohn's Disease, Ulcerative Colitis
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)
- Trial name
- NCT03283085
- Testing
- 25 mg Ontamalimab, 75 mg Ontamalimab
- Where
- 419 sites in United States, Argentina and 35 more
- Volunteers
- 557 people
- Sponsor
- Shire
Gastroduodenal Ulcerations, Erosion
Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults
The purpose of this study is to determine the subchronic gastrointestinal (GI) safety of PL3100 versus Naproxen in normal healthy volunteers.
- Trial name
- NCT01139190
- Testing
- PL3100, Naproxen
- Where
- 2 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- PLx Pharma
Ulcerative Colitis
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
The primary objective of this study is to evaluate the efficacy of golimumab in maintaining a clinical response in participants with moderate-to-severe ulcerative colitis.
- Trial name
- GO-COLITIS (NCT02092285)
- Testing
- Golimumab
- Where
- United Kingdom
- Volunteers
- 205 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis
This study aims to characterize the changes on intestinal microbiota pattern associated with the use of golimumab in order to determine if intestinal microbiota markers may correlate with golimumab therapeutic effect in patients…
- Trial name
- GOLI2015 (NCT03018925)
- Testing
- Golimumab
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Pyoderma Gangrenosum
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
- Trial name
- NCT03137160
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Ohio State University